GEN-MKT-18-7897-A
Dec 16, 2016 | Blogs, Forensic | 0 comments
There is a lot you can tell from a droplet of blood as it’s snapshot of what could be present in a body at any given moment. In the following application note, LC-MS/MS Screening of 64 New Psychoactive Substances Using Dried Blood Spots, researchers did just that as they used dried blood spots (DBS) opposed to the more invasive venipuncture technique to detect 64 psychoactive substances in samples.
To accomplish this research a highly sensitive QTRAP® LC-MS/MS was used in Multiple Reaction Monitoring (MRM) mode using the Scheduled MRM™ Algorithm. The importance of the method is that it can be expanded upon which is useful to government attempts at control the advent of new substances. When the European Monitoring System for Drugs and Addiction (EMCDDA) launched its Early Warning Program notification of new substances, for example, reported cases increased from 14 in 2008 to 98 in 2015.
As public awareness and government regulations like this become more profound, more accurate and less invasive testing methods are essential to keeping psychoactive substances off store shelves. In addition to sensitivity, the specimens can be easily stored, shipped, and maintained for future forensic testing.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
At SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.
Posted by
You must be logged in to post a comment.
Share this post with your network